Serious bacterial infections can result in costly hospital stays and complications, particularly if initial treatments fail to improve the patient’s condition. Novel antibiotic treatments have the potential to reduce these costs by averting the impacts of antimicrobial resistance, but a limited number of innovative treatments are currently in development. This lack of development is due to limited returns on investment stemming from generally effective generic treatments and good stewardship practices, which limit use, coupled with a fee-for-service payment structure that rewards high-volume use. However, as resistance to generic antibiotics increases, a robust arsenal of novel antibiotics is needed to ensure public health. This roundtable will explore the value of antibiotics and whether payment reform models could enable more sustainable utilization and development.